• Olaparib (AZD2281): Translating PARP Inhibition into Precisi

  2026-07-27

  This thought-leadership article explores the mechanistic rationale and strategic use of Olaparib (AZD2281) in translational cancer research, emphasizing its role in exploiting DNA repair vulnerabilities in BRCA-associated tumors, enhancing tumor radiosensitization, and overcoming chemoresistance. Drawing on current evidence and recent findings on resistance pathways, the discussion provides actionable guidance for researchers designing next-generation combination therapies.

• Olaparib (AZD2281, Ku-0059436): Reliable Solutions for DNA D

  2026-07-26

  This article delivers actionable, scenario-driven strategies for optimizing DNA damage response and cytotoxicity assays using Olaparib (AZD2281, Ku-0059436) (SKU A4154). Drawing on recent literature and validated protocols, it guides researchers through practical challenges in BRCA-deficient cancer research, highlighting the reproducibility and performance advantages of APExBIO's formulation.

• Phenylmethanesulfonyl Fluoride (PMSF): Precision in Protein

  2026-07-25

  Phenylmethanesulfonyl fluoride (PMSF) enables irreversible serine protease inhibition, safeguarding protein samples with unmatched fidelity for Western blot and cell signaling workflows. Learn how APExBIO’s PMSF empowers reproducible extraction protocols and discover troubleshooting strategies rooted in recent advances on protease inhibitor use.

• Perphenazine: Mechanistic Versatility for Translational Rese

  2026-07-24

  This thought-leadership article explores Perphenazine’s unique mechanistic profile as a dopamine D2 receptor antagonist, highlighting its role in neuropharmacology, mitochondria-mediated cell death, opioid tolerance suppression, and emerging host-directed antibacterial strategies. We integrate recent mechanistic evidence and translational guidance, positioning APExBIO’s Perphenazine (SKU B6157) as a multi-domain research catalyst for advanced experimental workflows.

• Epacadostat (INCB024360): Applied Protocols in Immuno-Oncolo

  2026-07-24

  Epacadostat (INCB024360) empowers immuno-oncology studies by enabling precise IDO1 inhibition and robust immune-metabolic modulation. This guide details optimized workflows, practical troubleshooting, and unique advantages for translational research integrating standardized whole-blood assays.

• STING Agonist-1 in Immunology: Protocols, Insights & Trouble

  2026-07-23

  STING agonist-1 empowers immunology and cancer researchers to dissect B cell-driven antitumor immunity and tertiary lymphoid structure formation, building on recent mechanistic breakthroughs. This guide delivers best-practice workflows, optimization strategies, and troubleshooting tips for maximizing reproducibility using APExBIO's high-purity, DMSO-soluble small molecule.

• CXCR4 Antagonism: Bridging Mechanism to Translational Impact

  2026-07-23

  This thought-leadership article explores the mechanistic, experimental, and translational landscape of Mavorixafor hydrochloride (AMD-070 hydrochloride), a potent CXCR4 antagonist. It provides strategic guidance for translational researchers by integrating biological rationale, validation data, and real-world use cases, while highlighting clinical potential and the product’s unique strengths over standard resources.

• Masitinib (AB1010): Technical Guidance for Selective KIT/PDG

  2026-07-22

  Masitinib (AB1010) offers researchers a potent and selective tool for inhibiting KIT, PDGFRα, and PDGFRβ in targeted cancer, mastocytosis, and inflammation studies. It is best applied in DMSO-based workflows where high kinase selectivity is required; it should not be used in protocols needing water or ethanol solubility, or for broad-spectrum kinase inhibition.

• Capecitabine: Mechanism, Selectivity, and Oncology Benchmark

  2026-07-22

  Capecitabine, a fluoropyrimidine prodrug, delivers tumor-selective 5-FU via enzymatic activation in cancer tissues. Its efficacy in preclinical oncology models stems from its targeted apoptosis induction and favorable solubility profile. This article details its biochemical rationale, evidence, and integration into advanced tumor microenvironment workflows.

• Photothermal Therapy Enhances CD47 Blockade in OSCC Immunoth

  2026-07-21

  The reference study demonstrates that photothermal therapy (PTT), when combined with CD47 immune checkpoint blockade, synergistically boosts anti-tumor macrophage responses in oral squamous cell carcinoma (OSCC). By inducing calreticulin exposure and remodeling the extracellular matrix, this combination addresses two major barriers to effective macrophage-mediated tumor clearance.

• Isoprinosine for Viral Immunotherapy: Applied Workflows & In

  2026-07-21

  Isoprinosine (inosine pranobex) stands out as an immunomodulatory agent that not only inhibits viral replication but also enhances host immune responses. This article delivers actionable protocols, troubleshooting tips, and advanced applications—bridging mechanistic insights from herpesvirus research to practical antiviral assay optimization.

• PDHA1 Succinylation Drives Immune Escape in Cholangiocarcino

  2026-07-20

  A recent study demonstrates that PDHA1 succinylation at lysine 83 in cholangiocarcinoma promotes immune evasion by suppressing macrophage antigen presentation via α-ketoglutaric acid accumulation. Inhibiting this modification with CPI-613 restores immune sensitivity and enhances chemotherapy efficacy, providing a new angle for overcoming resistance in this cancer.

• Perospirone (SM-9018 Freebase): Applied Neurovascular Resear

  2026-07-20

  Perospirone (SM-9018 freebase) empowers translational studies at the intersection of neuropsychiatric and cardiovascular research, uniquely enabling concurrent modeling of serotonergic, dopaminergic, and vascular ion channel mechanisms. This guide delivers protocol-ready workflows, troubleshooting strategies, and practical insights for maximizing reproducibility and specificity in complex disease models.

• Isoprinosine and CLCC1: Next-Gen Strategies for Viral Egress

  2026-07-19

  Explore how Isoprinosine (inosine pranobex) redefines antiviral immunotherapy by targeting viral egress mechanisms, including CLCC1-mediated pathways. Gain practical insights on advanced applications and protocol optimization for acute respiratory and herpesvirus infections.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Research Work

  2026-07-18

  Masitinib (AB1010) is a selective tyrosine kinase inhibitor for precise inhibition of KIT, PDGFRα, and PDGFRβ in cancer, mastocytosis, and inflammatory disease research. It should be used exclusively in DMSO-based protocols requiring high specificity and is not suitable for workflows needing aqueous or ethanol solubility or broad kinase inhibition.

16693 records 1/1113 page Next 12345 下5页 Last page